

MAR 06 2008

Remarks and Arguments

Claims 31-63 are currently pending in the application. In response to the present office action, Applicants have amended claim 31 and have, without prejudice, cancelled claims 51 and 52. Page 20 of the application presently on file has been amended to correct the salt of the end products. The reactant "Ms<sub>2</sub>O" when used as a reactant in the scheme to produce MES121 and compounds thereafter in the scheme, and compounds 143 and 156, provides "MsOH" salts and not, as originally given, "TsOH". This was an obvious typographical error. By these amendments, Applicants submit that *no new matter has been added*.

Priority claim

The Examiner states that a certified copy of the priority document is not part of the application currently on file and therefore the priority date is considered to be the actual U.S. filing date (02/01/2006) of the application. In response, Applicants respectfully direct the Examiner's attention to a Notice of Acceptance of the current application under 35 U.S.C. 371 and 37 C.F.R. 1.497 mailed by the Office on 06/09/2006. The Notice states that the priority documents were received by the Office on 02/01/2006. Thus, it is respectfully submitted that Applicants have satisfied the conditions for claiming priority.

Claim Rejections Under 35 USC § 102

The Examiner has rejected claims 31-36, 38-40, 43-46, 48-49 and 52 has been anticipated by Davis et al (U.S. Patent number 5,057,614). While in no way acquiescing through the Examiner's position and merely to expedite allowance of the application, Applicants have amended claim 31 to include with the proviso that "when X<sup>1</sup>-X<sup>3</sup> are all C, R<sup>1</sup>-R<sup>3</sup> are all H, X<sup>1</sup> is CH, X<sup>6</sup> is C, R<sup>5</sup> is H, X<sup>10</sup> is CH, X<sup>6</sup>-X<sup>8</sup> are all C, R<sup>6</sup>-R<sup>8</sup> are all H, and X<sup>9</sup> is CH, then R<sup>1</sup> is not CH<sub>3</sub>". By this amendment, claim 31, and claims dependent therefrom, is not anticipated by Davis et al. The Examiner is respectfully requested to reconsider his position and remove this rejection.




Double patenting

The Examiner has rejected claim 50 on the ground of nonstatutory obviousness-type double patenting as being unpatentable over claim 6 of U.S. Patent number 7,129,250. Furthermore, the Examiner has rejected claim 51 on the ground of nonstatutory obviousness-type double patenting as being unpatentable over claim






7 of U.S. Patent number 7,129,250. While in no way acquiescing to the Examiner's position and merely to expedite allowance of the application, Applicants have cancelled claims 50 and 51, without prejudice, thereby rendering the rejection moot.






Claim Rejections Under 35 USC § 112





The Examiner has rejected claims 31-36, 38-40, 42-46 and 48-52 as failing to comply with the written description requirement. In particular, the Examiner states that there is improper IUPAC nomenclature which would create ambiguity as to what is actually possessed. In response, Applicants submit the following Table to help clarify the IUPAC names in terms of their corresponding chemical structure, as requested by the Examiner.

Compound number	IUPAC name	Compound structure
121	3-(1-(3-hydroxypropyl)-1H-indol-3-yl)-4-(1H-indol-1-yl)-1H-pyrrole-2,5-dione	
124	3-(5-(benzyloxy)-1-(3-hydroxypropyl)-1H-indol-3-yl)-4-(1H-indol-1-yl)-1H-pyrrole-2,5-dione	
125	3-(1-(3-hydroxypropyl)-1H-indol-3-yl)-4-(3-methyl-1H-indol-1-yl)-1H-pyrrole-2,5-dione	





Compound number	IUPAC name	Compound structure
126	3-(5-(benzyloxy)-1H-indol-1-yl)-4-(1-(3-hydroxypropyl)-1H-indol-3-yl)-1H-pyrrole-2,5-dione	
127	3-(1-(3-hydroxypropyl)-1H-indol-3-yl)-4-(2-methyl-1H-indol-1-yl)-1H-pyrrole-2,5-dione	
128	3-(1H-benzo[d]imidazol-1-yl)-4-(1-(3-hydroxypropyl)-1H-indol-3-yl)-1H-pyrrole-2,5-dione	
129	3-(5-(benzyloxy)-1-(3-hydroxypropyl)-1H-indol-3-yl)-4-(3-methyl-1H-indol-1-yl)-1H-pyrrole-2,5-dione	
130	3-(1-(3-hydroxypropyl)-1H-indol-3-yl)-4-(1H-pyrrolo[2,3-b]pyridin-1-yl)-1H-pyrrole-2,5-dione	

Compound number	IUPAC name	Compound structure
131	3-(5-(benzyloxy)-1-(3-hydroxypropyl)-1H-indol-3-yl)-4-(2-methyl-1H-indol-1-yl)-1H-pyrrole-2,5-dione	
132	3-(5-fluoro-1H-indol-1-yl)-4-(1-(3-hydroxypropyl)-1H-indol-3-yl)-1H-pyrrole-2,5-dione	
133	3-(1-(3-(dimethylamino)propyl)-1H-indol-3-yl)-4-(1H-indol-1-yl)-1H-pyrrole-2,5-dione	
136	3-(5-(benzyloxy)-1-(3-(dimethylamino)propyl)-1H-indol-3-yl)-4-(1H-indol-1-yl)-1H-pyrrole-2,5-dione	
137	3-(1-(3-(dimethylamino)propyl)-1H-indol-3-yl)-4-(3-methyl-1H-indol-1-yl)-1H-pyrrole-2,5-dione	





Compound number	IUPAC name	Compound structure
138	3-(5-(benzyloxy)-1H-indol-1-yl)-4-(1-(3-(dimethylamino)propyl)-1H-indol-3-yl)-1H-pyrrole-2,5-dione	 (CH <sub>3</sub> ) <sub>2</sub> N
139	3-(1-(3-(dimethylamino)propyl)-1H-indol-3-yl)-4-(2-methyl-1H-indol-1-yl)-1H-pyrrole-2,5-dione	 (CH <sub>3</sub> ) <sub>2</sub> N
140	3-(1H-benzo[d]imidazol-1-yl)-4-(1-(3-(dimethylamino)propyl)-1H-indol-3-yl)-1H-pyrrole-2,5-dione	 (CH <sub>3</sub> ) <sub>2</sub> N
141	3-(5-(benzyloxy)-1-(3-(dimethylamino)propyl)-1H-indol-3-yl)-4-(3-methyl-1H-indol-1-yl)-1H-pyrrole-2,5-dione	 (CH <sub>3</sub> ) <sub>2</sub> N
142	3-(1-(3-(dimethylamino)propyl)-1H-indol-3-yl)-4-(1H-pyrrolo[2,3-b]pyridin-1-yl)-1H-pyrrole-2,5-dione	 (CH <sub>3</sub> ) <sub>2</sub> N

Compound number	IUPAC name	Compound structure
143	3-(3-(4-(1H-indol-1-yl)-2,5-dioxo-2,5-dihydro-1H-pyrrol-3-yl)-1H-indol-1-yl)propyl carbamimidothioate	
146	3-(3-(4-(3-methyl-1H-indol-1-yl)-2,5-dioxo-2,5-dihydro-1H-pyrrol-3-yl)-1H-indol-1-yl)propyl carbamimidothioate	
147	3-(3-(4-(5-(benzyloxy)-1H-indol-1-yl)-2,5-dioxo-2,5-dihydro-1H-pyrrol-3-yl)-1H-indol-1-yl)propyl carbamimidothioate	
148	3-(3-(4-(1H-indol-1-yl)-2,5-dioxo-2,5-dihydro-1H-pyrrol-3-yl)-5-(benzyloxy)-1H-indol-1-yl)propyl carbamimidothioate	





Compound number	IUPAC name	Compound structure
149	3-(5-(benzyloxy)-3-(4-(7-methyl-1H-indol-1-yl)-2,5-dioxo-2,5-dihydro-1H-pyrrol-3-yl)-1H-indol-1-yl)propyl carbamimidothioate	
150	3-(5-(benzyloxy)-3-(4-(2-methyl-1H-indol-1-yl)-2,5-dioxo-2,5-dihydro-1H-pyrrol-3-yl)-1H-indol-1-yl)propyl carbamimidothioate	
151	3-(3-(4-(2-methyl-1H-indol-1-yl)-2,5-dioxo-2,5-dihydro-1H-pyrrol-3-yl)-1H-indol-1-yl)propyl carbamimidothioate	
152	3-(3-(2,5-dioxo-4-(1H-pyrrolo[2,3-b]pyridin-1-yl)-2,5-dihydro-1H-pyrrol-3-yl)-1H-indol-1-yl)propyl carbamimidothioate	

Compound number	IUPAC name	Compound structure
153	3-(3-(4-(1H-indol-1-yl)-2,5-dioxo-2,5-dihydro-1H-pyrrol-3-yl)-5-methoxy-1H-indol-1-yl)propyl carbamimidothioate	
154	3-(3-(4-(1H-indol-1-yl)-2,5-dioxo-2,5-dihydro-1H-pyrrol-3-yl)-5-fluoro-1H-indol-1-yl)propyl carbamimidothioate	
155	3-(3-(4-(5-fluoro-1H-indol-1-yl)-2,5-dioxo-2,5-dihydro-1H-pyrrol-3-yl)-1H-indol-1-yl)propyl carbamimidothioate	
156	3-(1-(3-(4,5-dihydro-1H-imidazol-2-ylthio)propyl)-1H-indol-3-yl)-4-(1H-indol-1-yl)-1H-pyrrole-2,5-dione	




Compound number	IUPAC name	Compound structure
159	3-(3-(4-(indolin-1-yl)-2,5-dioxo-2,5-dihydro-1H-pyrrol-3-yl)-1H-indol-1-yl)propyl carbamimidothioate	
160	3-(3-(4-(1H-indol-1-yl)-2,5-dioxo-2,5-dihydro-1H-pyrrol-3-yl)-5-(phenylthiomethyl)-1H-indol-1-yl)propyl carbamimidothioate	
161	3-(1-(3-azidopropyl)-1H-indol-3-yl)-4-(1H-indol-1-yl)-1H-pyrrole-2,5-dione	
162	3-(1-(3-aminopropyl)-1H-indol-3-yl)-4-(1H-indol-1-yl)-1H-pyrrole-2,5-dione	

Compound number	IUPAC name	Compound structure
163	3-(3-(3-hydroxypropyl)-1H-indol-1-yl)-4-(1H-indol-3-yl)-1H-pyrrole-2,5-dione	
164	3-(3-(3-hydroxypropyl)-1H-indol-1-yl)-4-(1-methyl-1H-indol-3-yl)-1H-pyrrole-2,5-dione	
165	3-(5-(benzyloxy)-1H-indol-3-yl)-4-(3-(3-hydroxypropyl)-1H-indol-1-yl)-1H-pyrrole-2,5-dione	
166	3-(1-(4-(1H-indol-3-yl)-2,5-dioxo-2,5-dihydro-1H-pyrrol-3-yl)-1H-indol-3-yl)propyl carbamimidothioate	
167	3-(1-(4-(1-methyl-1H-indol-3-yl)-2,5-dioxo-2,5-dihydro-1H-pyrrol-3-yl)-1H-indol-3-yl)propyl carbamimidothioate	

Compound number	IUPAC name	Compound structure
168	3-(1-(4-(5-(benzyloxy)-1-methyl-1H-indol-3-yl)-2,5-dioxo-2,5-dihydro-1H-pyrrol-3-yl)-1H-indol-3-yl)propyl carbamimidothioate	
169	3-(3-(3-(dimethylamino)propyl)-1H-indol-1-yl)-4-(1-methyl-1H-indol-3-yl)-1H-pyrrole-2,5-dione	
170	3-(3-(3-(4,5-dihydro-1H-imidazol-2-ylthio)propyl)-1H-indol-1-yl)-4-(1-methyl-1H-indol-3-yl)-1H-pyrrole-2,5-dione	
171	3-(3-(3-(3-azidopropyl)-1H-indol-1-yl)-4-(1-methyl-1H-indol-3-yl)-1H-pyrrole-2,5-dione	

MAR 06 2008

Compound number	IUPAC name	Compound structure
172	3-(3-(3-aminopropyl)-1H-indol-1-yl)-4-(1-methyl-1H-indol-3-yl)-1H-pyrrole-2,5-dione	

**Attorney Docket Number**

Please note that the attorney docket number for this case has changed. The new docket number is **L80003396US2**. It is respectfully requested that this number be used on all future correspondence in connection with this application.


If any further extension of time is necessary, the United States Patent and Trademark Office is hereby petitioned for such an extension and may charge any necessary fees to our **Deposit Account no. 50-4067**.

If any further fee, **whatsoever**, with respect to the present application is due, the United States Patent and Trademark Office is in any event hereby authorized to charge such further amount to our **Deposit Account no. 50-4067**.

In light of the foregoing amendments and comments, favourable reconsideration is respectfully requested.

Respectfully submitted,

**GOWLING LAFLEUR HENDERSON, LLP**

  
Philip A. Swain, Ph.D.  
Reg. No 55,978  
1 Place Ville Marie, 37<sup>th</sup> Floor  
Montreal, Quebec, H3B 3P4  
Canada  
Tel.: (514) 392-9562  
Fax: (514) 878-1450  
Docket No.: L80003396US2

Date: March 6<sup>th</sup> 2008